GeneHealth - Your precision medicine

Neurodegeneration With Brain Iron Accumulation 4

Disease Details

Family Health Simplified

Buy Membership

Description: Neurodegeneration with brain iron accumulation 4 (NBIA4) is a rare, inherited neurological disorder characterized by the progressive accumulation of iron in the brain, leading to movement problems and cognitive decline.

One-sentence description: NBIA4 is a rare genetic disorder that causes progressive neurological decline due to iron accumulation in the brain.
Type: Neurodegeneration with brain iron accumulation 4 (NBIA4) is an autosomal recessive disorder.
Signs And Symptoms: Neurodegeneration with brain iron accumulation type 4 (NBIA4) is part of a group of rare genetic disorders characterized by abnormal accumulation of iron in the brain. Signs and symptoms of NBIA4 may include:

1. **Motor Symptoms**: Progressive dystonia (involuntary muscle contractions), parkinsonism (tremors, stiffness, slow movement), and spasticity.
2. **Cognitive Impairment**: Decline in intellectual and cognitive functions.
3. **Psychiatric Symptoms**: Mood swings, depression, and other behavioral changes.
4. **Eye Abnormalities**: Visual disturbances and retinal degeneration.
5. **Speech and Swallowing Difficulties**: Dysarthria (trouble speaking) and dysphagia (trouble swallowing).

The onset and progression of symptoms can vary, with some individuals experiencing a faster or more severe course than others. Treatment is usually symptomatic and supportive.
Prognosis: Neurodegeneration with brain iron accumulation 4 (NBIA4) is a rare genetic disorder that typically leads to progressive neurological impairment due to abnormal iron accumulation in the brain. The prognosis for individuals with NBIA4 is generally poor, as the condition is progressive and currently lacks a cure. The severity and rate of progression can vary among affected individuals, but many experience significant disability over time. Supportive care and symptom management are the primary approaches to treatment.
Onset: Neurodegeneration with Brain Iron Accumulation 4 (NBIA 4) typically has an onset in late childhood to early adulthood. The median age of onset is around the second decade of life.
Prevalence: The prevalence of Neurodegeneration with Brain Iron Accumulation 4 (NBIA4) is not well-defined due to its rarity, but it is considered an extremely rare disorder. Specific prevalence numbers are not available in medical literature, indicating it affects only a very small number of individuals worldwide.
Epidemiology: Neurodegeneration with brain iron accumulation 4 (NBIA 4), also known as beta-propeller protein-associated neurodegeneration (BPAN), is a rare genetic disorder. The exact prevalence is unknown, but it is estimated to be very rare, affecting fewer than 1 in a million individuals. BPAN is typically caused by mutations in the WDR45 gene located on the X chromosome. Most cases are sporadic, but familial cases have been reported. As with other NBIA disorders, BPAN leads to progressive neurodegeneration, with iron accumulation predominantly affecting the brain.
Intractability: Yes, neurodegeneration with brain iron accumulation 4 (NBIA4), also known as mitochondrial membrane protein-associated neurodegeneration (MPAN), is generally considered intractable. There is currently no cure for NBIA4, and available treatments primarily focus on managing symptoms rather than halting or reversing the disease progression.
Disease Severity: Neurodegeneration with brain iron accumulation (NBIA) consists of a group of rare genetic disorders, including NBIA type 4. The severity of NBIA type 4 can vary significantly among affected individuals. It often presents with progressive neurological symptoms such as dystonia, parkinsonism, and cognitive decline, which tend to worsen over time. The disease severity and progression rate can lead to substantial impairment in daily functioning and may decrease life expectancy. Severity is individualized and can be influenced by specific genetic mutations and other factors.

Regarding nanotechnological applications (nan), research is ongoing, but no definitive treatments or significant interventions specifically utilizing nanotechnology have been mainstream for NBIA type 4 yet. Current treatment focuses on managing symptoms and supportive care.
Healthcare Professionals: Disease Ontology ID - DOID:0110738
Pathophysiology: Neurodegeneration with brain iron accumulation 4 (NBIA4) is a subtype of NBIA characterized by iron deposition in the brain, particularly in the basal ganglia. The underlying pathophysiology involves mutations in the C19orf12 gene, which is believed to play a role in lipid metabolism and mitochondrial function. These mutations disrupt normal cell processes, leading to iron accumulation and progressive neurodegeneration with symptoms such as motor dysfunction, dystonia, and cognitive decline. The exact mechanisms remain under investigation, but oxidative stress and mitochondrial abnormalities are thought to contribute significantly to the disease progression.
Carrier Status: Neurodegeneration with brain iron accumulation 4 (NBIA4) is inherited in an autosomal recessive manner. Carriers, individuals with only one copy of the mutated gene, typically do not show symptoms. However, when two carriers have a child, there is a 25% chance the child will inherit the disease, a 50% chance the child will be a carrier, and a 25% chance the child will neither be affected nor a carrier.
Mechanism: Neurodegeneration with brain iron accumulation type 4 (NBIA4), also known as Kufor-Rakeb syndrome, involves iron accumulation in the brain, particularly in the basal ganglia.

Mechanism:
- NBIA4 is primarily caused by mutations in the ATP13A2 gene. This gene encodes a lysosomal P-type ATPase involved in metal ion transport.
- The dysfunction of ATP13A2 leads to impaired lysosomal degradation and autophagy processes, contributing to cellular toxicity and neurodegeneration.

Molecular Mechanisms:
- Mutations in ATP13A2 result in defective protein trafficking and lysosomal function. This causes failure in clearing misfolded proteins and damaged organelles, leading to cellular stress.
- Abnormal iron homeostasis due to disrupted ATP13A2 activity leads to iron accumulation in the brain. Excess iron catalyzes the production of reactive oxygen species (ROS), causing oxidative damage and neuroinflammation.

Essentially, the breakdown in cellular maintenance and iron regulation mechanisms due to ATP13A2 mutations results in progressive neurodegeneration characteristic of NBIA4.
Treatment: For neurodegeneration with brain iron accumulation 4 (NBIA 4), there is no cure or universally effective treatment. However, management typically focuses on symptom relief and maintaining quality of life. Therapeutic strategies may include:

1. **Iron Chelation Therapy:** Desferoxamine and deferiprone are sometimes used to reduce iron accumulation in the brain.
2. **Medications:** Treatments may target specific symptoms, such as using dopamine agonists or anticholinergic drugs for dystonia and spasticity.
3. **Physical Therapy:** Rehabilitation efforts can help maintain mobility and reduce muscle stiffness.
4. **Deep Brain Stimulation (DBS):** In some cases, DBS may alleviate severe dystonia.

Patients should be managed by a multidisciplinary team for optimal care, involving neurologists, physical therapists, and other healthcare professionals.
Compassionate Use Treatment: Neurodegeneration with brain iron accumulation (NBIA) type 4, also known as Beta-Propeller Protein-Associated Neurodegeneration (BPAN), is a rare genetic disorder. Compassionate use or experimental treatments may include:

1. **Iron Chelation Therapy**: Although primarily used for other conditions, iron chelators like deferiprone are sometimes used off-label in NBIA disorders to reduce iron accumulation in the brain.

2. **Deferiprone**: Some clinical trials and case reports have evaluated the efficacy of deferiprone in managing symptoms by binding to excess iron and facilitating its removal.

3. **Gene Therapy**: Experimental approaches, including the use of gene therapy to correct the underlying genetic defect (WDR45 gene) responsible for BPAN, are being researched.

4. **Antioxidants**: High doses of vitamin E and coenzyme Q10 are sometimes used off-label to reduce oxidative stress, although evidence supporting their efficacy is limited.

5. **p62 Activators**: Research into p62 activators, which promote autophagy (cellular cleanup processes), holds potential for treating BPAN, given the WDR45 gene's role in autophagy.

Always consult with a healthcare provider or specialist for the most current and personalized treatment options.
Lifestyle Recommendations: For Neurodegeneration with Brain Iron Accumulation 4 (NBIA4), there are no specific lifestyle recommendations tailored to this rare condition due to its genetic and progressive nature. However, general recommendations for managing similar neurodegenerative conditions may include:

1. **Regular Medical Follow-Up:** Consistent monitoring by healthcare professionals, including neurologists and specialists in movement disorders.

2. **Balanced Diet:** A nutritious diet rich in antioxidants might support overall brain health. Consultation with a dietitian can tailor a diet plan to the individual’s needs.

3. **Physical Therapy:** Engaging in regular physical therapy to maintain mobility and muscle strength, and to manage spasticity and other motor symptoms.

4. **Occupational Therapy:** Employing techniques and adaptive strategies to assist with daily living activities and maintain independence as long as possible.

5. **Speech Therapy:** Assistance with speech and swallowing difficulties by utilizing exercises and adaptive strategies.

6. **Mental Health Support:** Accessing psychological support or counseling to manage the emotional and mental challenges of living with a chronic condition.

7. **Social Engagement:** Staying socially active and maintaining a support network to improve quality of life.

Note that these recommendations should not replace medical advice, and it is crucial to work closely with healthcare providers to tailor recommendations according to individual needs.
Medication: Neurodegeneration with brain iron accumulation 4 (NBIA4) is a rare genetic disorder characterized by abnormal accumulation of iron in the brain, leading to progressive neurological symptoms. As of now, there are no specific medications approved solely for NBIA4. Treatment primarily focuses on managing symptoms and may include:

1. **Antispasmodic drugs**: To help control muscle stiffness and spasms.
2. **Antiepileptic drugs**: Used if the patient experiences seizures.
3. **Botulinum toxin injections**: Can be used for managing dystonia, which is involuntary muscle contractions.
4. **Iron chelation therapy**: Although not specifically approved for NBIA4, this may be used off-label in an attempt to reduce iron accumulation.
5. **Supportive care**: Physical therapy, occupational therapy, and speech therapy to manage motor and speech difficulties.

It's essential for patients to work closely with a neurologist who specializes in movement disorders to tailor the treatment plan to their specific needs.
Repurposable Drugs: Neurodegeneration with brain iron accumulation 4 (NBIA4) is a rare genetic disorder characterized by abnormal iron deposition in the brain, leading to progressive neurological deterioration. Research on repurposable drugs for NBIA4 is limited, but some agents with potential therapeutic effects in related conditions include:

1. **Deferiprone**: An iron chelator that has been used in other NBIA disorders to reduce brain iron levels and alleviate symptoms.
2. **Deferasirox**: Another iron chelator that has shown promise in preliminary studies.
3. **Pantothenate kinase activators**: These can help improve mitochondrial function, which is often impaired in NBIA diseases.

Consultation with a healthcare provider and ongoing research are crucial for determining appropriate treatments.
Metabolites: Neurodegeneration with brain iron accumulation 4 (NBIA4), also known as Kufor-Rakeb syndrome, is associated with the accumulation of iron in the brain. The specific metabolites involved in NBIA4 are not fully understood, but oxidative stress markers, dopamine metabolism alterations, and disruptions in iron metabolism are typically noted. These metabolic changes can be investigated using advanced techniques such as MRI and spectroscopy to assess iron deposition and metabolite profiles in the brain.
Nutraceuticals: For neurodegeneration with brain iron accumulation 4 (NBIA4), nutraceuticals have not been established as an effective treatment. The primary focus for managing the condition includes symptomatic treatments and supportive care. Given the progressive nature of the disease, research continues into various therapeutic avenues, but as of now, no nutraceuticals have been proven to alter the course of NBIA4.
Peptides: Neurodegeneration with brain iron accumulation 4 (NBIA4) involves abnormal accumulation of iron in the brain, leading to progressive neurodegeneration. Research on therapeutic approaches for NBIA4 may investigate the use of peptides and nanotechnology:

1. **Peptides:** Therapeutic peptides could potentially be designed to target and modulate specific pathways involved in iron metabolism, reducing iron accumulation and its toxic effects on neurons. However, detailed and disease-specific peptide therapies are still largely in the experimental stages.

2. **Nanotechnology:** Nanoparticles can be engineered for targeted drug delivery to the brain. This technology could be used to deliver iron-chelating agents or neuroprotective compounds directly to affected areas, improving treatment efficacy and reducing side effects.

Active research is ongoing to better understand these treatments' roles in managing NBIA4.